Suda Pharmaceuticals Ltd Долг / собственный капитал
Что обозначает Долг / собственный капитал в Suda Pharmaceuticals Ltd?
Долг / собственный капитал Suda Pharmaceuticals Ltd является 0.18
Какое определение для Долг / собственный капитал?
Соотношение долга к собственному капиталу - это финансовое соотношение, показывающее относительную пропорцию собственного капитала и долга, используемых для финансирования активов компании.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Долг / собственный капитал компаний в Health Care сектор на ASX по сравнению с Suda Pharmaceuticals Ltd
Что делает Suda Pharmaceuticals Ltd?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Компании с долг / собственный капитал похож на Suda Pharmaceuticals Ltd
- Treasury Metals имеет Долг / собственный капитал из 0.18
- Treasury Metals имеет Долг / собственный капитал из 0.18
- Hangzhou Arcvideo Technology Co имеет Долг / собственный капитал из 0.18
- Clarity Gold имеет Долг / собственный капитал из 0.18
- AMTD IDEA имеет Долг / собственный капитал из 0.18
- Nevada Sunrise Gold имеет Долг / собственный капитал из 0.18
- Suda Pharmaceuticals Ltd имеет Долг / собственный капитал из 0.18
- Yorkton Ventures имеет Долг / собственный капитал из 0.18
- Chembond Chemicals имеет Долг / собственный капитал из 0.18
- Exelixis имеет Долг / собственный капитал из 0.18
- Shires Income Plc имеет Долг / собственный капитал из 0.18
- Capital VC имеет Долг / собственный капитал из 0.18
- Vital Mobile имеет Долг / собственный капитал из 0.18